

# For your determined patients with mNSCLC

## Consider CYRAMZA + erlotinib

- CYRAMZA + erlotinib demonstrated 19.4 months of median PFS vs 12.4 months with erlotinib alone in the ITT population<sup>6</sup>
- In patients with exon 21 mutation, CYRAMZA + erlotinib improved median PFS by 8.2 months vs erlotinib alone<sup>12</sup>

**CYRAMZA + erlotinib is a 1L EGFR-TKI option that significantly improves median PFS and supports the subsequent use of targeted therapies at progression<sup>6,12,15</sup>**

